NeuroSense Therapeutics (NRSN) Stock Price, Quote, News & History

Q: What sector and industry does NeuroSense Therapeutics (NRSN) operate in?

NeuroSense Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

NeuroSense Therapeutics Ltd (NRSN) Stock Price, Quote, News & History

NRSNNASDAQ

Trade with Public

$0.9399

0.06998.03%

At close: Feb 6, 4:00 PM EST

$0.9300

-0.0099-1.05%

After Hours: Feb 6, 6:44 PM EST

Overview

News Earnings Analyst Ratings Short Interest Stock Report

Key Statistics

Open

$0.87

Close

$0.94

Volume / Avg.

152.05K / 332.77K

Day Range

$0.86 - $0.96

52 Wk Range

0.68 - 2.60

Market Cap

$27.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.25%

Days to Cover

2.34

Recent Neurosense Therapeutics Ltd News

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating.

Vandana Singh

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Avi Kapoor

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-8.39M

Investing Cash Flow (TTM)

-13.00K

Financing Cash Flow (TTM)

7.90M

Free Cash Flow (TTM)

-8.39M

Capital Expenditure (TTM)

-5.00K

Net Change in Cash (TTM)

-501.00K

Analyst Trends and Forecast

1

Aug 25

1

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$27.66M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-38.50%

Earnings Yield % (FWD)

-19.25%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.02

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$666.00K

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.87

Close

$0.94

Volume / Avg.

152.05K / 332.77K

Day Range

$0.86 - $0.96

52 Wk Range

0.68 - 2.60

Market Cap

$27.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.25%

Days to Cover

2.34

About

Sector

Health Care

Industry

Biotechnology

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy NeuroSense Therapeutics (NRSN) stock?

A

You can purchase shares of NeuroSense Therapeutics (NASDAQ:NRSN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are NeuroSense Therapeutics (NRSN) competitors?

A

Other companies in NeuroSense Therapeutics’s space includes: Outlook Therapeutics Inc (NASDAQ:OTLK), Serina Therapeutics Inc (AMEX:SER), Skye Bioscience Inc (NASDAQ:SKYE), Intensity Therapeutics Inc (NASDAQ:INTS) and Evaxion AS (NASDAQ:EVAX).

Q

What is the forecast, or price target, for NeuroSense Therapeutics (NRSN) stock?

A

NeuroSense Therapeutics has a consensus price target of $10.75.

Q

What is the current price for NeuroSense Therapeutics (NRSN)?

A

The stock price for NeuroSense Therapeutics (NASDAQ: NRSN) is $0.93 last updated February 6, 2026 at 6:44 PM EST.

Q

Does NeuroSense Therapeutics (NRSN) pay a dividend?

A

There are no upcoming dividends for NeuroSense Therapeutics.

Q

When is NeuroSense Therapeutics (NASDAQ:NRSN) reporting earnings?

A

NeuroSense Therapeutics does not have any upcoming earnings scheduled.

Q

Is NeuroSense Therapeutics (NRSN) going to split?

A

There is no upcoming split for NeuroSense Therapeutics.

Q

What sector and industry does NeuroSense Therapeutics (NRSN) operate in?

A

NeuroSense Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Outlook Therapeutics Inc

SER

Intensity Therapeutics Inc

PTN

Key Statistics

Open

$0.87

Close

$0.94

Volume / Avg.

152.05K / 332.77K

Day Range

$0.86 - $0.96

52 Wk Range

0.68 - 2.60

Market Cap

$27.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.25%

Days to Cover

2.34

Recent Neurosense Therapeutics Ltd News

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating.

Vandana Singh

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Avi Kapoor

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-8.39M

Investing Cash Flow (TTM)

-13.00K

Financing Cash Flow (TTM)

7.90M

Free Cash Flow (TTM)

-8.39M

Capital Expenditure (TTM)

-5.00K

Net Change in Cash (TTM)

-501.00K

Analyst Trends and Forecast

1

Aug 25

1

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$27.66M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-38.50%

Earnings Yield % (FWD)

-19.25%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.02

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$666.00K

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.87

Close

$0.94

Volume / Avg.

152.05K / 332.77K

Day Range

$0.86 - $0.96

52 Wk Range

0.68 - 2.60

Market Cap

$27.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.25%

Days to Cover

2.34

About

Sector

Health Care

Industry

Biotechnology

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry